Clinical Trial Update: Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ranolazine for incomplete vessel revascularization after PCI in people with coronary artery disease and angina; the study is completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina Pectoris
• Coronary Artery Disease

Drugs mentioned

• Ranexa (ranolazine)

Snippet

Sponsor: Gilead Sciences | Conditions: Coronary Artery Disease, Angina Pectoris | Phase 3 | Status: COMPLETED | Results posted: 2016-07-15